CN1537852A - Anti coxsackie viruse action of quinolixiding kind alkaloid - Google Patents
Anti coxsackie viruse action of quinolixiding kind alkaloid Download PDFInfo
- Publication number
- CN1537852A CN1537852A CNA031164056A CN03116405A CN1537852A CN 1537852 A CN1537852 A CN 1537852A CN A031164056 A CNA031164056 A CN A031164056A CN 03116405 A CN03116405 A CN 03116405A CN 1537852 A CN1537852 A CN 1537852A
- Authority
- CN
- China
- Prior art keywords
- virus
- medicine
- coxsackie
- group
- viral myocarditis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Sophoridine is disclosed, which can suppress the Coxsackie group B virus and can be used to treat viral myocarditis, so it can be used to prepare the medicines for resisting Coxsackie group B virus and treating viral myocarditis.
Description
Technical field
The present invention relates to a kind of quinolizidine kind alkaloid, more specifically refer to sophorine (Sophoridine), through the pharmacological testing proof effectively to the viral myocarditis treatment,, it can be used in preparation treatment viral myocarditis medicine.
Background technology
Viral myocarditis is caused that by multiple virus (as Coxsackie virus B) soaking into myocardial cell's degeneration necrosis, a matter mononuclearcell is a kind of common clinical of major lesions, the serious harm human health.
At present, the main method of doctor trained in Western medicine clinical treatment viral myocarditis is to use common antiviral drug, immunosuppressor, Interferon, rabbit and myocardial cell's nutrition agent etc., but curative effect is unsatisfactory.
In recent years, pharmacological research and clinical trial show that Chinese medicine demonstrates very big advantage in the clinical treatment of viral myocarditis.At present have only indivedual kinds at the Chinese patent medicine of viral myocarditis clinically, and be crude extract preparation (as stilbene winter chin or cheek heart oral liquid), mostly be the doctor greatly from the prescription decoction of medicinal ingredients of intending, urgent need is developed determined curative effect, effective constituent and pharmacological action are clear, formulation advanced person, easy administration, Chinese medicine preparation stable and controllable for quality.
Sophorine (Sophoridine) can extract from plants such as kuh-seng, Herba Sophorae alopecuroidis and obtain, bibliographical information has pharmacological actions such as analgesia, antitumor, anti-arrhythmia, but does not see the report of anti-Coxsackie virus B (CoxsackieGroup B Virus) and treatment viral myocarditis.
Summary of the invention
The objective of the invention is to overcome the weak point that conventional multi-flavor decoction of medicinal ingredients exists, adopt chemical process extraction separation from plants such as kuh-seng to go out a kind of quinolizidine kind alkaloid---sophorine, through pharmacological testing, confirm that this compound can use in the medicine of preparation treatment viral myocarditis.
The extracting method of sophorine following (is example with the kuh-seng):
Chinese medicine kuh-seng meal floods 3 times with the methyl alcohol room temperature, each 24h.Methanol extract liquid concentrates the back thin up, transfer PH3～4 with rare HCl, ether is washed 2 times, adds NaOH after the gained acid liquid concentrates and transfers to pH3, adds the dichloromethane extraction alkaloid, residue after the gained dichloromethane extract reclaims is dissolved in the chloroform, add an amount of ether then, with solution concentration, debris adopts alumina column chromatography, with sherwood oil-acetone wash-out, separate obtaining pure compound sophorine (Sophoridine).Its molecular formula is C
15H
24ON
2, molecular weight is 248.
Its chemical structural formula is as follows:
The sophorine extraction process is with reference to " chemical composition of Chinese materia medica extraction separation handbook ", and Yang Yun edits, China Traditional Chinese Medicine Publishing House, first version in 1998.
The sophorine that the present invention adopts aforesaid method to extract acquisition at first carries out the test of pesticide effectiveness.
Sophorine is divided into two dosage groups, and the Balb/c mouse is divided into 4 groups at random.
1, normal control group: do not give sophorine, virus inoculation is not only given equivalent distilled water;
2, virus control group: every abdominal cavity inoculation 0.1mlCVB
3Virus liquid (TCID
50=10
-7.5, 10
5Doubly dilution).
3, administration group I-high dosage: the same method inoculation CVB
3Virus liquid is irritated stomach sophorine 0.15mmol/kgd (sophorine is mixed with 2.85mg/ml with physiological saline) on the same day, and successive administration 7 days was observed 15 days;
4, administration group II-low dosage: irritate the stomach sophorine, dosage is 0.075mmol/kgd;
Result's virus group is dead 80%, and medicine of the present invention can significantly reduce by coxsackie B
3The mortality ratio of the mice with viral myocarditis that virus causes, high dose group can be reduced to 35%, and low dose group can be reduced to 50%.
The present invention adopts the dosage grouping of above-mentioned test, and successive administration 7 days was observed 15 days, then mouse was dissected, and scale mouse body weight before dissection weighs its cardiac weight again after the dissection, calculate its cardiac index then.Method of calculation are:
Cardiac index=heart weight/body weight
After animal was by virus infection, food ration reduced, and body weight reduces, and therefore heart expands, and fibrosis takes place and becomes heavy, so can weigh the lesion degree of heart with cardiac index, cardiac index is big more, and heart change is serious more.
The result shows that the high dose group of medicine of the present invention can significantly reduce by coxsackie B
3The cardiac index of the mice with viral myocarditis that virus causes.
The present invention adopts dosage, the grouping of above-mentioned test, successive administration 7 days, observed 15 days, then mouse is dissected, the cardiac muscle sample places multigelation that virion is discharged, get viral dilution liquid myocardium sample viral suspension is done 10 times of dilutions continuously, it is inoculated in (96 orifice plate) on the Hep-2 cell, measure the virus titer of myocardium sample.
Experimental result shows that the high dose group of medicine of the present invention can significantly reduce by coxsackie B
3The Cardiovirus titre of the mice with viral myocarditis that virus causes.
Annotate: above pharmacological testing method is with reference to " modern pharmacology experimental technique " (volume two, P
1425, Zhang Juntian chief editor, combined publication society of China Concord Medical Science University of Beijing Medical University, version in 1998).
Embodiment
Below in conjunction with specific embodiment the present invention is further elaborated, but it is not had any restriction.
Embodiment 1: medicine of the present invention is to the influence test of mice with viral myocarditis mortality ratio
Get 56 of Balb/c mouse, be divided into 4 groups at random.
The normal control group: 6, do not give medicine of the present invention, also virus inoculation is not only given equivalent distilled water.
The virus control group: 10, every abdominal cavity inoculation 0.1mlCVB
3Virus liquid (TCID
50=10
-7.5, 10
5Doubly dilution).
Administration group: high dosage: 20, inoculation CVB
3Virus liquid is irritated stomach by 0.15mmol/kgd on the same day and is given medicine of the present invention, and successive administration 7 days was observed to the 15th day.
Low dosage: 20, virus inoculation and give medicine of the present invention, dosage is 0.075mmol/kgd
The situations such as the mental status, diet, hair color and death of animal during the observed and recorded administration (raising).
The result: two dosage groups of medicine of the present invention all can significantly reduce by coxsackie B
3The mortality ratio of the mice with viral myocarditis that virus causes sees Table 1.
Table 1 medicine of the present invention is to the influence of mice with viral myocarditis mortality ratio
Group number of animals (only) mortality ratio (routine number)
Normal control group 60 (0)
Virus control group 10 80% (8)
Administration high dose group 20 35% (7)
*
Administration low dose group 20 50% (10)
*
Annotate: adopt chi square test, the administration group is organized relatively with virus,
*Statistical significance is arranged.
Embodiment 2: medicine of the present invention is to the influence test of mice with viral myocarditis cardiac index
Balb/c mice group and dosage are with embodiment 1.Successive administration 7 days is observed the 15th day, and all mouse are all dissected.The body weight of scale mouse before dissection weighs its cardiac weight again after the dissection.
Cardiac index=heart weight/body weight
After animal was by virus infection, food ration reduced, and body weight reduces, and therefore heart expands, fibrosis takes place and becomes weight, so can weigh the lesion degree of heart with cardiac index, cardiac index is big more, and heart change is serious more.
The result: the high dose group of medicine of the present invention can significantly reduce by coxsackie B
3The cardiac index of the mice with viral myocarditis that virus causes sees Table 2.
Table 2 medicine of the present invention is to the influence of mice with viral myocarditis cardiac index
Group cardiac index (* 10
-3)
Normal control group 5.80 ± 0.60
Virus control group 6.56 ± 1.33
Administration high dose group 6.08 ± 1.17
*
Administration low dose group 6.40 ± 0.84
Annotate: the administration group compares with the virus group:
*P＜0.05,
*P＜0.01
Embodiment 3: medicine of the present invention is to the influence test of mice with viral myocarditis Cardiovirus titre
Balb/c mice group and dosage are with embodiment 1.Successive administration 7 days is observed the 15th day, and all mouse are all dissected.After myocardium sample placed 0.5ml sterilized water multigelation three times, virion will discharge from cardiac muscle, get viral dilution liquid myocardium sample viral suspension is done 10 continuously
1-10
5Doubly dilution is inoculated in (96 orifice plate) on the Hep-2 cell with it, and the TCID of observation of cell was observed in each 3 hole of sample inoculation continuously 5 days
50, TCID appears in record cell the last day
50The viral dilution degree.Recording method: as the minimum extent of dilution that cytopathic freeze thawing virus liquid more than 50% occurs is 10
-5, be TCID
50=10
-5, for ease of statistics, get negative logarithm it is converted, promptly-LgTCID
50=5.The mean value of getting 3 holes is the viral neutralization index of this sample.
The size of neutralization index is directly proportional with virus virulence, and the big more then virulence of index is strong more; A little less than the little then virulence of index, the antiviral drug effect of prompting medicine.
The result: the high dose group of medicine of the present invention can significantly reduce by coxsackie B
3The Cardiovirus titre of the mice with viral myocarditis that virus causes the results are shown in Table 3.
Table 3 medicine of the present invention is to the influence of mice with viral myocarditis Cardiovirus titre
Virus titer
Normal control 0
Virus control 1.26
Administration high dose group 0.67
*
Administration low dose group 1.2
Annotate: the administration group compares with the virus group:
*P＜0.05,
*P＜0.01
Annotate: above pharmacological testing method is with reference to " modern pharmacology experimental technique " (volume two, P
1425, Zhang Juntian chief editor, combined publication society of China Concord Medical Science University of Beijing Medical University, version in 1998).
Claims (1)
1, a kind of following structure:
Quinolizidine kind alkaloid in sophorine, it is characterized in that it can be used for preparing in anti-Coxsackie virus B and the treatment viral myocarditis medicine to use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031164056A CN1537852A (en) | 2003-04-14 | 2003-04-14 | Anti coxsackie viruse action of quinolixiding kind alkaloid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031164056A CN1537852A (en) | 2003-04-14 | 2003-04-14 | Anti coxsackie viruse action of quinolixiding kind alkaloid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1537852A true CN1537852A (en) | 2004-10-20 |
Family
ID=34320338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031164056A Pending CN1537852A (en) | 2003-04-14 | 2003-04-14 | Anti coxsackie viruse action of quinolixiding kind alkaloid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1537852A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101598733B (en) * | 2009-04-16 | 2013-01-23 | 北京科兴生物制品有限公司 | EV71 virus neutralization epitope detection kit or reagent and preparation method thereof |
| CN104546839A (en) * | 2015-02-05 | 2015-04-29 | 中国医学科学院医学实验动物研究所 | Novel application of quinolizidine alkaloid |
-
2003
- 2003-04-14 CN CNA031164056A patent/CN1537852A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101598733B (en) * | 2009-04-16 | 2013-01-23 | 北京科兴生物制品有限公司 | EV71 virus neutralization epitope detection kit or reagent and preparation method thereof |
| CN104546839A (en) * | 2015-02-05 | 2015-04-29 | 中国医学科学院医学实验动物研究所 | Novel application of quinolizidine alkaloid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1824269A (en) | Xinshenghua oral liquid and its preparation method | |
| CN1472220A (en) | Triterpene extracts from achyranthes roots and their use in medicine against osteoporosis | |
| CN1872105A (en) | Application of holly and extractive in preparing medication for anti virus | |
| CN1799564A (en) | Application of valeriana wallichii and its extract in preparation of medicine for treating anxiety neurosis | |
| CN1813711A (en) | Use of isoflavone compound | |
| CN1537852A (en) | Anti coxsackie viruse action of quinolixiding kind alkaloid | |
| CN1189203C (en) | Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer | |
| CN1310650C (en) | Application of saponins in the preparing process of coxsackie virus resisting medicine | |
| CN115400194A (en) | Traditional Chinese medicine composition for treating childhood epidemic and application thereof | |
| CN1265797C (en) | Application of timosaponin A3 for preparing medicine for treating No.2 type diabetes mellitus | |
| CN1261143C (en) | Separating preparation process of effective part and active component of influenza virus resisting medicine | |
| CN1312077A (en) | Composite component comprising the effective extracts of licorice and lightyellow sophora and its application | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN112168877A (en) | Traditional Chinese medicine composition for preventing and treating coccidiosis and preparation method thereof | |
| CN1468602A (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN1259043C (en) | Application of salvia acid in pharmacy | |
| CN1426783A (en) | Application of evodiamine in the preparation of medicine | |
| CN1839867A (en) | Medicinal composition with heat-clearing, fire-draining and detoxification function | |
| CN1406585A (en) | Medicinal composition for viral myocarditis | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN103356717B (en) | Rhizoma Dryopteris Crassirhizomatis extract and its use in preparation of viral disease controlling medicines | |
| CN101028311A (en) | Use of selaginella tamariscina | |
| CN85108520A (en) | A kind of preparation method of haemostatic used in gynaecololgy and obstetrics | |
| CN100339126C (en) | Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process | |
| CN1254255C (en) | Oral liquor for curing cerebral hemorrhage and its preparation method by using leach |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |